Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-02

AUTHORS

Erin R. Gardner, Martha Kelly, Eric Springman, Kyoung-jin Lee, Haiqing Li, William Moore, William D. Figg

ABSTRACT

LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest. Screening in the NCI60 cancer cell lines resulted in a mean GI50 of approximately 100 nM. Here, we report the results of testing in multiple mouse xenograft models and angiogenesis assays, along with bioavailability studies. To determine the antiangiogenic activity of LP-261, both in vitro and ex vivo experiments were performed. Human umbilical vein endothelial cells (HUVECs) were incubated with LP-261 at 50 nM to 10 μM. LP-261 was also tested in a rat aortic ring assay, from 20 nM to 10 μM. Multiple mouse xenograft studies were performed to assess in vivo antitumor activity. LP-261 was tested as a single agent in colon adenocarcinoma (SW620) and prostate cancer (LNCaP and PC3) xenografts, evaluating several different dosing schedules. LP-261 was also used in combination with bevacizumab in the SW620 xenograft model. LP-261 also exhibited high oral bioavailability and apparent lack of efflux by intestinal transporters such as ABCB1. LP-261 is a very potent inhibitor of angiogenesis, preventing microvessel outgrowth in the rat aortic ring assay and HUVEC cell proliferation at nanomolar concentrations. Complete inhibition of tumor growth was achieved in the PC3 xenograft model and shown to be schedule dependent. Excellent inhibition of tumor growth in the SW620 model was observed, comparable with paclitaxel. Combining oral, low dose LP-261 with bevacizumab led to significantly improved tumor inhibition. Oral LP-261 is very effective at inhibiting tumor growth in multiple mouse xenograft models and is well tolerated. More... »

PAGES

90-97

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-010-9520-5

DOI

http://dx.doi.org/10.1007/s10637-010-9520-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009908165

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20820910


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Human Umbilical Vein Endothelial Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intestinal Absorption", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intestinal Mucosa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isonicotinic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Nude", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neovascularization, Pathologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neovascularization, Physiologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Paclitaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Permeability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Sprague-Dawley", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tubulin Modulators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Burden", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Xenograft Model Antitumor Assays", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Leidos (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419407.f", 
          "name": [
            "Clinical Pharmacology Program, SAIC-Frederick, NCI-Frederick, 21702, Frederick, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gardner", 
        "givenName": "Erin R.", 
        "id": "sg:person.0721047257.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721047257.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Ansaris, 19422, Blue Bell, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kelly", 
        "givenName": "Martha", 
        "id": "sg:person.01333645644.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333645644.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Ansaris, 19422, Blue Bell, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Springman", 
        "givenName": "Eric", 
        "id": "sg:person.0644070255.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644070255.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Ansaris, 19422, Blue Bell, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Kyoung-jin", 
        "id": "sg:person.0652513644.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652513644.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Haiqing", 
        "id": "sg:person.014727362367.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014727362367.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Viamet Pharmaceuticals (United States)", 
          "id": "https://www.grid.ac/institutes/grid.431044.6", 
          "name": [
            "Viamet Pharmaceuticals, Inc, 27560, Morrisville, NC, USA", 
            "Ansaris, 19422, Blue Bell, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moore", 
        "givenName": "William", 
        "id": "sg:person.01035320654.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035320654.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute, 20892, Bethesda, MD, USA", 
            "Medical Oncology Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Figg", 
        "givenName": "William D.", 
        "id": "sg:person.011506723157.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011506723157.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1600-0463.2004.apm1120306.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003640167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2008.01.082", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014133471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-008-9137-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016778037", 
          "https://doi.org/10.1007/s10637-008-9137-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-008-9137-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016778037", 
          "https://doi.org/10.1007/s10637-008-9137-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019159796", 
          "https://doi.org/10.1038/nrc1369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019159796", 
          "https://doi.org/10.1038/nrc1369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00171-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031316872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa072113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033842397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cbc.2008.s.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042638805"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0593", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045570909"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1951", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053488336", 
          "https://doi.org/10.1038/nrc1951"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1951", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053488336", 
          "https://doi.org/10.1038/nrc1951"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm100659v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055951746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm100659v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055951746"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-02", 
    "datePublishedReg": "2012-02-01", 
    "description": "LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest. Screening in the NCI60 cancer cell lines resulted in a mean GI50 of approximately 100 nM. Here, we report the results of testing in multiple mouse xenograft models and angiogenesis assays, along with bioavailability studies. To determine the antiangiogenic activity of LP-261, both in vitro and ex vivo experiments were performed. Human umbilical vein endothelial cells (HUVECs) were incubated with LP-261 at 50 nM to 10 \u03bcM. LP-261 was also tested in a rat aortic ring assay, from 20 nM to 10 \u03bcM. Multiple mouse xenograft studies were performed to assess in vivo antitumor activity. LP-261 was tested as a single agent in colon adenocarcinoma (SW620) and prostate cancer (LNCaP and PC3) xenografts, evaluating several different dosing schedules. LP-261 was also used in combination with bevacizumab in the SW620 xenograft model. LP-261 also exhibited high oral bioavailability and apparent lack of efflux by intestinal transporters such as ABCB1. LP-261 is a very potent inhibitor of angiogenesis, preventing microvessel outgrowth in the rat aortic ring assay and HUVEC cell proliferation at nanomolar concentrations. Complete inhibition of tumor growth was achieved in the PC3 xenograft model and shown to be schedule dependent. Excellent inhibition of tumor growth in the SW620 model was observed, comparable with paclitaxel. Combining oral, low dose LP-261 with bevacizumab led to significantly improved tumor inhibition. Oral LP-261 is very effective at inhibiting tumor growth in multiple mouse xenograft models and is well tolerated.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-010-9520-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2726649", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5246872", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2726363", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2343593", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "name": "Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab", 
    "pagination": "90-97", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-010-9520-5"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2f33b5509d2f32d4b6908e9376230597e9f6c48f18f89d58c62d59e30495c66c"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009908165"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20820910"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-010-9520-5", 
      "https://app.dimensions.ai/details/publication/pub.1009908165"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91464_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-010-9520-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-010-9520-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-010-9520-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-010-9520-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-010-9520-5'


 

This table displays all metadata directly associated to this object as RDF triples.

286 TRIPLES      21 PREDICATES      69 URIs      51 LITERALS      39 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-010-9520-5 schema:about N016799c8c94a4509851ff4b0b4dcca4d
2 N05f79de6349a449c9e40ca9f5038f5f7
3 N0860fcf708d74e4d9f1672cb6efe5863
4 N08ba7aeef68e4923b1e43a33ef866d03
5 N1cf5e93b90ad47d497bde6f80625fc7f
6 N30d8d1498f5748d6b4988d41a5e8f74b
7 N38f588cae0a246448fc42dfea5618ada
8 N3d53410a8d1140fa8a35de979b45c97e
9 N3f052e21b959473aa250ec9fd0d99c2c
10 N3f4398d741c8417d94863bb415cb0cc5
11 N45e0050bdde448dda4cc43595c4576a9
12 N570b3dbbb94a43f2afe3bcc6bd584979
13 N59cbf0aeb277411b9675d85d6e1d3d07
14 N606fa8755e6d4dc4853c1e72f6f546d7
15 N6a8bc0421eeb4901bd13f3312cb8b1a4
16 N75017deec88949a6bccb368f47936655
17 N7ce9bec0a5ad426bb0f3dcbe63442ee4
18 N84d47b7b39d44dd08898b257a08577eb
19 N909df741539543fabbfd8e8fde8cd04a
20 N94f12069dc654b07a1403f4d25935cb8
21 N98cd1af5e5994d76b222fa1b6e1c8faf
22 N98ed08941860460ba802af68a23011ef
23 Na01aa3657d0b41538d3d991c800c1c27
24 Na8da98a1582c4c64b532a79ee83f99f4
25 Ncc189c7a13a04a3795fea7207e6bc6a4
26 Nd413b2ffc0b94c0f87f77d3f9e100d14
27 Ndabbfdff404d45beadfcf3f79a06c57d
28 Ndd4729003ad84ccab3cbd6ac379a650a
29 Nf560e61401f54df7b7c3a86e38f2790e
30 Nf9856c33429849f99b91b6b89bb592be
31 anzsrc-for:11
32 anzsrc-for:1112
33 schema:author Nfb21a8f33f7c4599919660f82318cc45
34 schema:citation sg:pub.10.1007/s10637-008-9137-0
35 sg:pub.10.1038/nrc1369
36 sg:pub.10.1038/nrc1951
37 https://doi.org/10.1016/j.eururo.2008.01.082
38 https://doi.org/10.1016/s0959-8049(01)00171-x
39 https://doi.org/10.1021/jm100659v
40 https://doi.org/10.1056/nejmoa072113
41 https://doi.org/10.1111/j.1600-0463.2004.apm1120306.x
42 https://doi.org/10.1158/1078-0432.ccr-08-0593
43 https://doi.org/10.3816/cbc.2008.s.001
44 schema:datePublished 2012-02
45 schema:datePublishedReg 2012-02-01
46 schema:description LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest. Screening in the NCI60 cancer cell lines resulted in a mean GI50 of approximately 100 nM. Here, we report the results of testing in multiple mouse xenograft models and angiogenesis assays, along with bioavailability studies. To determine the antiangiogenic activity of LP-261, both in vitro and ex vivo experiments were performed. Human umbilical vein endothelial cells (HUVECs) were incubated with LP-261 at 50 nM to 10 μM. LP-261 was also tested in a rat aortic ring assay, from 20 nM to 10 μM. Multiple mouse xenograft studies were performed to assess in vivo antitumor activity. LP-261 was tested as a single agent in colon adenocarcinoma (SW620) and prostate cancer (LNCaP and PC3) xenografts, evaluating several different dosing schedules. LP-261 was also used in combination with bevacizumab in the SW620 xenograft model. LP-261 also exhibited high oral bioavailability and apparent lack of efflux by intestinal transporters such as ABCB1. LP-261 is a very potent inhibitor of angiogenesis, preventing microvessel outgrowth in the rat aortic ring assay and HUVEC cell proliferation at nanomolar concentrations. Complete inhibition of tumor growth was achieved in the PC3 xenograft model and shown to be schedule dependent. Excellent inhibition of tumor growth in the SW620 model was observed, comparable with paclitaxel. Combining oral, low dose LP-261 with bevacizumab led to significantly improved tumor inhibition. Oral LP-261 is very effective at inhibiting tumor growth in multiple mouse xenograft models and is well tolerated.
47 schema:genre research_article
48 schema:inLanguage en
49 schema:isAccessibleForFree false
50 schema:isPartOf N9379c56e48314f07bd9cc015c5a4202e
51 Nba3f8073a7434d7abedcbd38f04df3ba
52 sg:journal.1094201
53 schema:name Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab
54 schema:pagination 90-97
55 schema:productId N2f76932a9dd44663806da2c9351c5124
56 N8c2132c14a8e49a497dcec2e721b83f6
57 Nc5d1b8e2ba6c4db7968a713f5771ef56
58 Nc8ce5875883745e09ace27add0b26fae
59 Ncb12ce5c301243519743c02bd8aa09fa
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009908165
61 https://doi.org/10.1007/s10637-010-9520-5
62 schema:sdDatePublished 2019-04-15T09:03
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher N478fd098c4c84e44a5c835cc530def7c
65 schema:url http://link.springer.com/10.1007%2Fs10637-010-9520-5
66 sgo:license sg:explorer/license/
67 sgo:sdDataset articles
68 rdf:type schema:ScholarlyArticle
69 N016799c8c94a4509851ff4b0b4dcca4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Antibodies, Monoclonal, Humanized
71 rdf:type schema:DefinedTerm
72 N05f79de6349a449c9e40ca9f5038f5f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Sulfonamides
74 rdf:type schema:DefinedTerm
75 N0860fcf708d74e4d9f1672cb6efe5863 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Isonicotinic Acids
77 rdf:type schema:DefinedTerm
78 N08ba7aeef68e4923b1e43a33ef866d03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Tubulin Modulators
80 rdf:type schema:DefinedTerm
81 N14a9621a4ae845feb677b04f19d3a73f rdf:first sg:person.011506723157.25
82 rdf:rest rdf:nil
83 N14c64509002a47d5bfd244519fd4b1b1 rdf:first sg:person.01035320654.72
84 rdf:rest N14a9621a4ae845feb677b04f19d3a73f
85 N1b6e154c23c0460fb077207637d2c6e3 rdf:first sg:person.0652513644.65
86 rdf:rest N3617f3c78036497ebc3192a5ea8c1666
87 N1cf5e93b90ad47d497bde6f80625fc7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Cell Line, Tumor
89 rdf:type schema:DefinedTerm
90 N2f76932a9dd44663806da2c9351c5124 schema:name doi
91 schema:value 10.1007/s10637-010-9520-5
92 rdf:type schema:PropertyValue
93 N30d8d1498f5748d6b4988d41a5e8f74b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Cell Proliferation
95 rdf:type schema:DefinedTerm
96 N3617f3c78036497ebc3192a5ea8c1666 rdf:first sg:person.014727362367.78
97 rdf:rest N14c64509002a47d5bfd244519fd4b1b1
98 N38f588cae0a246448fc42dfea5618ada schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Permeability
100 rdf:type schema:DefinedTerm
101 N3d53410a8d1140fa8a35de979b45c97e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Bevacizumab
103 rdf:type schema:DefinedTerm
104 N3f052e21b959473aa250ec9fd0d99c2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Biological Availability
106 rdf:type schema:DefinedTerm
107 N3f4398d741c8417d94863bb415cb0cc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Dose-Response Relationship, Drug
109 rdf:type schema:DefinedTerm
110 N45e0050bdde448dda4cc43595c4576a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Rats, Sprague-Dawley
112 rdf:type schema:DefinedTerm
113 N478fd098c4c84e44a5c835cc530def7c schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 N570b3dbbb94a43f2afe3bcc6bd584979 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Neovascularization, Pathologic
117 rdf:type schema:DefinedTerm
118 N59cbf0aeb277411b9675d85d6e1d3d07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Administration, Oral
120 rdf:type schema:DefinedTerm
121 N5df9013aef0d4d4a8e1aa5b630e2b13a schema:name Ansaris, 19422, Blue Bell, PA, USA
122 rdf:type schema:Organization
123 N606fa8755e6d4dc4853c1e72f6f546d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Rats
125 rdf:type schema:DefinedTerm
126 N6a8bc0421eeb4901bd13f3312cb8b1a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Neoplasms
128 rdf:type schema:DefinedTerm
129 N75017deec88949a6bccb368f47936655 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Angiogenesis Inhibitors
131 rdf:type schema:DefinedTerm
132 N7ce9bec0a5ad426bb0f3dcbe63442ee4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Neovascularization, Physiologic
134 rdf:type schema:DefinedTerm
135 N84d47b7b39d44dd08898b257a08577eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Mice
137 rdf:type schema:DefinedTerm
138 N8c2132c14a8e49a497dcec2e721b83f6 schema:name pubmed_id
139 schema:value 20820910
140 rdf:type schema:PropertyValue
141 N909df741539543fabbfd8e8fde8cd04a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Intestinal Absorption
143 rdf:type schema:DefinedTerm
144 N9379c56e48314f07bd9cc015c5a4202e schema:issueNumber 1
145 rdf:type schema:PublicationIssue
146 N94f12069dc654b07a1403f4d25935cb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Time Factors
148 rdf:type schema:DefinedTerm
149 N98cd1af5e5994d76b222fa1b6e1c8faf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Animals
151 rdf:type schema:DefinedTerm
152 N98ed08941860460ba802af68a23011ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Paclitaxel
154 rdf:type schema:DefinedTerm
155 Na01aa3657d0b41538d3d991c800c1c27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Antineoplastic Combined Chemotherapy Protocols
157 rdf:type schema:DefinedTerm
158 Na8da98a1582c4c64b532a79ee83f99f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Human Umbilical Vein Endothelial Cells
160 rdf:type schema:DefinedTerm
161 Nba3f8073a7434d7abedcbd38f04df3ba schema:volumeNumber 30
162 rdf:type schema:PublicationVolume
163 Nbcff40c484ad4df7aaa5a98b3cf9bed8 schema:name Ansaris, 19422, Blue Bell, PA, USA
164 rdf:type schema:Organization
165 Nc5d1b8e2ba6c4db7968a713f5771ef56 schema:name nlm_unique_id
166 schema:value 8309330
167 rdf:type schema:PropertyValue
168 Nc8ce5875883745e09ace27add0b26fae schema:name readcube_id
169 schema:value 2f33b5509d2f32d4b6908e9376230597e9f6c48f18f89d58c62d59e30495c66c
170 rdf:type schema:PropertyValue
171 Ncb12ce5c301243519743c02bd8aa09fa schema:name dimensions_id
172 schema:value pub.1009908165
173 rdf:type schema:PropertyValue
174 Ncc189c7a13a04a3795fea7207e6bc6a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Humans
176 rdf:type schema:DefinedTerm
177 Nd413b2ffc0b94c0f87f77d3f9e100d14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Tumor Burden
179 rdf:type schema:DefinedTerm
180 Ndabbfdff404d45beadfcf3f79a06c57d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Mice, Nude
182 rdf:type schema:DefinedTerm
183 Ndd4729003ad84ccab3cbd6ac379a650a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Xenograft Model Antitumor Assays
185 rdf:type schema:DefinedTerm
186 Nefc216515d2b461aaaabffc752687ac4 schema:name Ansaris, 19422, Blue Bell, PA, USA
187 rdf:type schema:Organization
188 Nf4ef0fbb595b4ab98b9651a5d531ea42 rdf:first sg:person.0644070255.66
189 rdf:rest N1b6e154c23c0460fb077207637d2c6e3
190 Nf560e61401f54df7b7c3a86e38f2790e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Intestinal Mucosa
192 rdf:type schema:DefinedTerm
193 Nf9856c33429849f99b91b6b89bb592be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Male
195 rdf:type schema:DefinedTerm
196 Nfb21a8f33f7c4599919660f82318cc45 rdf:first sg:person.0721047257.44
197 rdf:rest Nfe73bd78495649df8c572a748d6c0140
198 Nfe73bd78495649df8c572a748d6c0140 rdf:first sg:person.01333645644.38
199 rdf:rest Nf4ef0fbb595b4ab98b9651a5d531ea42
200 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
201 schema:name Medical and Health Sciences
202 rdf:type schema:DefinedTerm
203 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
204 schema:name Oncology and Carcinogenesis
205 rdf:type schema:DefinedTerm
206 sg:grant.2343593 http://pending.schema.org/fundedItem sg:pub.10.1007/s10637-010-9520-5
207 rdf:type schema:MonetaryGrant
208 sg:grant.2726363 http://pending.schema.org/fundedItem sg:pub.10.1007/s10637-010-9520-5
209 rdf:type schema:MonetaryGrant
210 sg:grant.2726649 http://pending.schema.org/fundedItem sg:pub.10.1007/s10637-010-9520-5
211 rdf:type schema:MonetaryGrant
212 sg:grant.5246872 http://pending.schema.org/fundedItem sg:pub.10.1007/s10637-010-9520-5
213 rdf:type schema:MonetaryGrant
214 sg:journal.1094201 schema:issn 0167-6997
215 1573-0646
216 schema:name Investigational New Drugs
217 rdf:type schema:Periodical
218 sg:person.01035320654.72 schema:affiliation https://www.grid.ac/institutes/grid.431044.6
219 schema:familyName Moore
220 schema:givenName William
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035320654.72
222 rdf:type schema:Person
223 sg:person.011506723157.25 schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
224 schema:familyName Figg
225 schema:givenName William D.
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011506723157.25
227 rdf:type schema:Person
228 sg:person.01333645644.38 schema:affiliation N5df9013aef0d4d4a8e1aa5b630e2b13a
229 schema:familyName Kelly
230 schema:givenName Martha
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333645644.38
232 rdf:type schema:Person
233 sg:person.014727362367.78 schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
234 schema:familyName Li
235 schema:givenName Haiqing
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014727362367.78
237 rdf:type schema:Person
238 sg:person.0644070255.66 schema:affiliation Nbcff40c484ad4df7aaa5a98b3cf9bed8
239 schema:familyName Springman
240 schema:givenName Eric
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644070255.66
242 rdf:type schema:Person
243 sg:person.0652513644.65 schema:affiliation Nefc216515d2b461aaaabffc752687ac4
244 schema:familyName Lee
245 schema:givenName Kyoung-jin
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652513644.65
247 rdf:type schema:Person
248 sg:person.0721047257.44 schema:affiliation https://www.grid.ac/institutes/grid.419407.f
249 schema:familyName Gardner
250 schema:givenName Erin R.
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721047257.44
252 rdf:type schema:Person
253 sg:pub.10.1007/s10637-008-9137-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016778037
254 https://doi.org/10.1007/s10637-008-9137-0
255 rdf:type schema:CreativeWork
256 sg:pub.10.1038/nrc1369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019159796
257 https://doi.org/10.1038/nrc1369
258 rdf:type schema:CreativeWork
259 sg:pub.10.1038/nrc1951 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053488336
260 https://doi.org/10.1038/nrc1951
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1016/j.eururo.2008.01.082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014133471
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1016/s0959-8049(01)00171-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031316872
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1021/jm100659v schema:sameAs https://app.dimensions.ai/details/publication/pub.1055951746
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1056/nejmoa072113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033842397
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1111/j.1600-0463.2004.apm1120306.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003640167
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1158/1078-0432.ccr-08-0593 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045570909
273 rdf:type schema:CreativeWork
274 https://doi.org/10.3816/cbc.2008.s.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042638805
275 rdf:type schema:CreativeWork
276 https://www.grid.ac/institutes/grid.419407.f schema:alternateName Leidos (United States)
277 schema:name Clinical Pharmacology Program, SAIC-Frederick, NCI-Frederick, 21702, Frederick, MD, USA
278 rdf:type schema:Organization
279 https://www.grid.ac/institutes/grid.431044.6 schema:alternateName Viamet Pharmaceuticals (United States)
280 schema:name Ansaris, 19422, Blue Bell, PA, USA
281 Viamet Pharmaceuticals, Inc, 27560, Morrisville, NC, USA
282 rdf:type schema:Organization
283 https://www.grid.ac/institutes/grid.48336.3a schema:alternateName National Cancer Institute
284 schema:name Medical Oncology Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, 20892, Bethesda, MD, USA
285 Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute, 20892, Bethesda, MD, USA
286 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...